Approach to resistant gram-negative bacterial pulmonary infections in patients with cystic fibrosis

Current Opinion in Pulmonary Medicine

Volumn 9, Issue 6, 2003, Pages 509-515

  Chernish, Robert N ^a   Aaron, Shawn D ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Antibiotic resistance; Bacteria; Cystic fibrosis; Microbiology

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLAVULANIC ACID; COLISTIN; IMIPENEM; INTEGRIN; MEROPENEM; MINOCYCLINE; PIPERACILLIN; TICARCILLIN; TOBRAMYCIN;

ANTIBIOTIC RESISTANCE; ARCHAEBACTERIUM; BACTERIAL MUTATION; BACTERIAL PNEUMONIA; BACTERIAL SURVIVAL; BACTERIUM ISOLATE; BIOFILM; BURKHOLDERIA CEPACIA; CHRONIC DISEASE; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG SENSITIVITY; GENE TRANSFER; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GROWTH, DEVELOPMENT AND AGING; HAEMOPHILUS INFLUENZAE; HUMAN; INFECTION RESISTANCE; LABORATORY TEST; LUNG INFECTION; MICROBIOLOGY; MULTIDRUG RESISTANCE; PATHOPHYSIOLOGY; PHYSIOLOGY; PLASMID; PREVALENCE; PSEUDOMONAS AERUGINOSA; REVIEW; SIDE EFFECT; SPONTANEOUS MUTATION; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA;

EID: 0142105980     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200311000-00011     Document Type: Review

References (70)

1. Khan TZ, Wagener JS, Bost T, et al.: Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995, 151:1075-1082.
2. Muhlebach MS, Stewart PW, Leigh MW, et al.: Quantitation of inflammatory responses to bacteria in young cystic fibrosis and control patients. Am J Respir Crit Care Med 1999, 160:186-191.
3. Balough K, McCubbin M, Weinberger M, et al.: The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis. Pediatr Pulmonol 1995, 20:63-70.
4. Ogrinc GB, Kampalath B, Tomashefski JFJ: Destruction and loss of bronchial cartilage in cystic fibrosis. Hum Pathol 1998, 29:65.
5. Durieu I, Peyrol S, Gindre D, et al.: Subepithelial fibrosis and degradation of the bronchial extracellular matrix in cystic fibrosis. Am J Respir Crit Care Med 1998, 158:580-588.
6. Prober CG, Walson PD, Jones J: Technical report: precautions regarding the use of aerosolized antibiotics. Committee on Infectious Diseases and Committee on Drugs. Pediatrics 2000, 106:E89.
7. Burns JL, Van Dalfsen JM, Shawar RM, et al.: Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999, 179:1190-1196.
8. MacLoed DL, Nelson LE, Shawar RM, et al.: Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment. J Infect Dis 2000, 181:1180-1184.
9. Cystic Fibrosis Foundation: Microbiology and infectious disease in cystic fibrosis (conference proceeding, V, sec 1), 1994:1-26.
10. Garey KW, Danziger LH, Rubinstein I: Tissue reparative effects of macrolide antibiotics in chronic inflammatory sinopulmonary diseases. Chest 2003, 123:261-265.
11. Schwab U, Giligan P, Janes J, et al.: In vitro activities of designed antimicrobial peptides against multidrug-resistant cystic fibrosis pathogens. Antimicrob Agents Chemother 1999, 43:1435-1440.
12. Rosenfeld M, Gibson RL, McNamara S, et al.: Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 2001, 32:356-366.
13. Emerson J, Rosenfeld M, McNamara S, et al.: Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002, 34:91-100.
14. Turner J, Cho Y, Dinh N-N, et al.: Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother 1998, 42:2206-2214.
15. Nixon GM, Armstrong DS, Carzino R, et al.: Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001, 138:699-704.
16. Rajan S, Saiman L: Pulmonary infections in patients with cystic fibrosis. Semin Respir Infect 2003, 17:47-56.
17. LiPuma JJ, Dasen SE, Nielson DW, et al.: Person-to-person transmission of Pseudomonas cepacia between patients with cystic fibrosis. Lancet 1990, 336:1094-1096.
18. Govan JR, Brown PH, Maddison J, et al.: Evidence of transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet 1993, 342:15-19.
19. Doring G, Jansen S, Noll H, et al.: Distribution and transmission of Pseudomonas aeruginosa and Burkholderia cepacia in a hospital ward. Pediatr Pulmonol 1996, 21:90-100.
20. Pegues DA, Carson LA, Tablan OC, et al.: Acquisition of Pseudomonas cepacia at summer camps for patients with cystic fibrosis. Summer camp study group. J Pediatr 1994, 124:694-702.
21. Vandamme P, Henry D, Coenye T, et al.: Burkholderia anthina sp. nov. and Burkholderia pyrrocinia, two additional Burkholderia cepacia complex bacteria, may confound results of new molecular diagnostic tools. FEMS Immunol Med Microbiol 2002, 33:143-149.
22. Coenye T, Vandamme P, Govan JR, et al.: Taxonomy and identification of the Burkholderia cepacia complex. J Clin Microbiol 2001, 39:3427-3436.
23. Mahenthiralingam E, Vandamme P, Campbell M, et al.: Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis 2001, 33:1469-1475.
24. Goss CH, Otto K, Aitken ML, et al.: Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. Am J Respir Crit Care Med 2002, 166:356-361. This was a cohort study, using the Cystic Fibrosis Foundation Registry. The study compared survival among patients with cystic fibrosis who acquired S. maltophilia and those who did not. Three-year survival was not significantly different in the two groups after controlling for P. aeruginosa coinfection and severity of disease.
25. Demko CA, Byard PJ, Davis PB: Gender differences in cystic fibrosis: Pseudomonas aeruginosa infection. J Clin Epidemiol 2003, 48:1041-1049.
26. Hancock REW, Speert DP: Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and impact on treatment. Drug Resist Update 2000, 3:255.
27. Livermore DM: Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin Infect Dis 2002, 34:634-640.
28. Poole K: Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. J Mol Microbiol Biotechnol 2003, 3:255-264.
29. Aires JR, Pechere JC, Van Delden C, et al.: Amino acid residues essential for function of the MexF efflux pump protein of Pseudomonas aeruginosa. Antimicrob Agent Chemother 2002, 46:2169-2173.
30. Masuda N, Sakagawa E, Ohya S, et al.: Contribution of the MexX-MexY-oprM efflux system to intrinsic resistance in Pseudomonas aeruginosa. Antimicrob Agent Chemother 2000, 44:2242-2246.
31. Mayer KH: Review of epidemic aminoglycoside resistance worldwide. Am J Med 1986, 80:56-64.
32. Oliver A, Cantón R, Campo P, et al.: High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000, 288:1251-1253.
33. Costerton JW, Geesey GG, Cheng KJ: How bacteria stick. Sci Am 1978, 238:86-95.
34. Costerton JW, Stewart PS, Greenberg EP: Bacterial biofilms: a common cause of persistent infections. Science 1999, 284:1318-1322.
35. Drenkard E, Ausubel FM: Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 2002, 416:740-743. This laboratory study showed that antibiotic-resistant phenotypic variants of P. aeruginosa with enhanced ability to form biofilms arise at a high frequency in the lungs of patients with cystic fibrosis. A regulatory protein that may control the conversion to antibiotic-resistant phenotypes was identified.
36. Singh PK, Schaefer AL, Parsek MR, et al.: Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000, 407:762-764.
37. Hentzer M, Teitzel G, Balzer G, et al.: Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function. J Bacteriol 2001, 183:5395-5401.
38. Singh PK, Parsek MR, Greenberg EP, et al.: A component of innate immunity prevents bacterial biofilm development. Nature 2002, 417:552-555.
39. Hoyle BD, Costerton JW: Bacterial resistance to antibodies: the role of biofilms. Prog Drug Res 1991, 37:91-105.
40. Flores G: Biofilm studies yield targets against cystic fibrosis. Drug Discov Today 2002, 7:1147-1148.
41. Hassett DJ, Cuppoletti J, Trapnell B, et al.: Anaerobic metabolism and quorum sensing by Pseudomonas aeruginosa biofilms in chronically infected cystic fibrosis airways: rethinking antibiotic treatment strategies and drug targets. Adv Drug Deliv Rev 2002, 54:1425-1443.
42. Prince AS: Biofilms, antimicrobial resistance, and airway infection. N Engl J Med 2002, 347:1110-1111. An introductory review on how biofilm formation may mediate antibiotic resistance and lead to chronic airway infection in the cystic fibrosis lung.
43. Worlitzsch D, Tarran R, Ulrich M, et al.: Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002, 109:317-325. This study showed that P. aeruginosa was located within hypoxic mucopurulent masses in airways of patients with cystic fibrosis. There were steep hypoxic gradients within thickened mucus on cystic fibrosis epithelial surfaces before infection. Motile P. aeruginosa deposited on cystic fibrosis airway surfaces and penetrated into hypoxic mucus zones and responded to this environment with increased alginate production. These studies indicate that novel therapies for cystic fibrosis include removal of hypoxic mucous plaques and antibiotics effective against P. aeruginosa adapted to anaerobic environments.
44. O'Toole GA: Microbiology: a resistance switch. Nature 2002, 416:695-696.
45. Greenberg EP: Pump up the versatility. Nature 2000, 406:947-948.
46. Davies DG, Parsek MR, Pearson JP, et al.: The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 1998, 280:295-298.
47. Gibson RL, Emerson J, McNamara S, et al.: Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003, 167:841-849. A small clinical trial of 21 children with cystic fibrosis which showed that treatment with 28 days of inhaled TOBI resulted in no P. aeruginosa detectable by bronchoscopy after 28 days in 8/8 treated patients.
48. Ryan G, Mukhopadhyay S, Singh M: Nebulised antipseudomonal antibiotics for cystic fibrosis (Cochrane review). The Cochrane Library 2003, Oxford: update software.
49. Ramsey BW, Pepe MS, Quan JM, et al.: Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1997, 340:23-30.
50. Dakin C, Henry RL, Field P, et al.: Defining an exacerbation of pulmonary disease in cystic fibrosis. Pediatr Pulmonol 2001, 31:436-442.
51. LiPuma J: Microbiological and immunologic considerations with aerosolized drug delivery. Chest 2001, 120:118S-123S.
52. Jensen T, Pederson SS, Garne S, et al.: Colisten inhalation therapy in cystic fibrosis with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987, 19:831-838.
53. Day AJ, Williams J, McKeown C, et al.: Evaluation of inhaled colimycin in children with cystic fibrosis [abstract]. Proceedings of the 10th International Cystic Fibrosis Congress 106. Sydney, 1988.
54. Littlewood JM, Miller MG, Ghoneim AT, et al.: Nebulised colimycin for early Pseudomonas colonization in cystic fibrosis. Lancet 1985, 1:865.
55. Valerius NH, Koch C, Hoiby N: Prevention of chronic Pseudomonas aeruginosa colonization in cystic fibrosis by early treatment. Lancet 1991, 338:725-726.
56. Hodson ME, Gallagher CG, Govan JR: A randomized clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002, 20:658-664.
57. Rosenfeld M, Emerson J, Williams-Warren J, et al.: Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001, 139:359-365.
58. Elphick HE, Tan A: Single versus combination intravenous antibiotic therapy for people with cystic fibrosis (Cochrane Review). The Cochrane Library 2003, Oxford: update software.
59. Smith AL, Doershuk C, Goldmann D, et al.: CF comparison of a β-lactam alone versus β-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. J Pediatr 1999, 134:413-421.
60. Regelmann WE, Elliott GR, Warwick WJ, et al.: Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990, 141:914-921.
61. Aaron SD, Ferris W, Henry DA, et al.: Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med 2000, 161:1206-1212.
62. Burns JL, Saiman L: Burkholderia cepacia infections in cystic fibrosis. Pediatr Infect Dis J 1999, 18:155-156.
63. Ceri H, Oison ME, Stremick C, et al.: The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J Clin Microbiol 1999, 37:1771-1776.
64. Aaron SD, Ferris W, Ramotar K, et al.: Single and combination antibiotic susceptibilities of planktonic, adherent and biofilm-grown Pseudomonas aeruginosa cultured from CF sputum. J Clin Microbiol 2002, 40:4172-4179. A laboratory-based study that showed that P. aeruginosa derived from patients with cystic fibrosis is more resistant to single and combination antibiotics when cultured as a biofilm compared with when it is cultured in planktonic conditions.
65. Hoiby N: New antimicrobials in the management of cystic fibrosis. J Antimicrol Chemother 2002, 49:235-238. This is a good review of new antibiotic strategies for management of cystic fibrosis lung infections.
66. Geller DE, Rosenfeld M, Waltz DA, et al.: Efficiency of pulmonary administration of tobramycin solution for inhalation in cystic fibrosis using an improved drug delivery system. Chest 2003, 123:28-36.
67. Fiel SB: Early aggressive intervention in cystic fibrosis-is it time to redefine our 'best practice' strategies? Chest 2003, 123:1-3.
68. Travis SM, Conway BA, Zabner J, et al.: Activity of abundant antimicrobials of the human airway. Am J Respir Cell Mol Biol 1999, 20:872-879. The investigators found that abundant airway antimicrobial factors kill common cystic fibrosis pathogens, although Burkholderia was relatively resistant. To study the antibacterial activity, they developed a rapid, sensitive, and quantitative in vitro luminescence assay. Because NaCl concentrations may be elevated in cystic fibrosis airway surface liquid, the investigators tested the effect of salt on antibacterial activity. The activity of individual factors and airway lavage fluid was inhibited by high ionic strength, and it was particularly sensitive to divalent cations. When studied at low NaCl concentrations, cystic fibrosis and non-cystic fibrosis airway lavage fluids contained similar levels of antibacterial activity.
69. Saiman L, Tabibi S, Starner TD, et al.: Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis. Antimicrob Agents Chemother 2001, 45:2838-2844.
70. Hancock RE, Patrzykat A: Clinical development of cationic antimicrobial peptides: from natural to novel antibiotics. Curr Drug Targets Infect Disord 2002, 2:79-83.